View PDF Version - RePub - Erasmus Universiteit Rotterdam

More documents

Recommendations

Info

Chapter 3.1 138 U i = Time to failure (HCC) for subject i if never exposed to glycyrrhizin (=counterfactual failure time) Glycyrrhizini (t) = The treatment status of subject i at timepoint t. The model that relates the observed data Ti and Glycyrrhizini (Ti) to the counterfactual failure time Ui is assumed to be: Ti Ui (ψ) = ∫ exp (ψ Glycyrrhizini (t)) dt 0 The model of U as a function of ψ describes the relation between the counterfactual failure time, the observed failure time and the use of glycyrrhizin over time. Acknowledgements The following Japanese investigators contributed to the study by sharing individual patient data: N. Izumi1 , J. Toyota2 , T. Aikawa3 , S. Fujiyama4 , K. Yasuda5 , A. Shibuya6 , Y. Hirose7 , H. Harada8 , S. Hige9 , G. Yamada10 , E. Tanaka11 , N. Ohno12 . 1Musashino Red Cross Hospital, Tokyo; 2Sapporo Kousei General Hospital, Hokkaido; 3Aikawa Internal Hospital, Ibaraki; 4Kumamoto University Hospital, Kumamoto; 5Kiyo kawa Hospital, Tokyo; 6Kitasato University East Hospital, Kanagawa; 7Yamanashi Central Prefectural Hospital, Yamanashi; 8National Tokyo Hospital, Tokyo; 9Hokkaido University School of Medicine, Hokkaido; 10Kawasaki Medical School, Okayama; 11Shinsu University School of Medicine, Nagano; 12Ohno Internal & Gastroenterology Clinic, Ehime. We thank mr. N. Yamamoto for his important contribution in the data collection. We thank the following experts for their highly valuable advice on study design and statistical methods: 1M.A. Hernán, T. Poynard2 , T. Stijnen3 , S. Iino4 and N. Hayashi5 . 1 Department of Epidemiology, School of Public Health, Harvard University, Boston MA, USA. 2Service d’Hépato- Gastroenterologie, Groupe Hospitalier Pitié Salpétrière, Paris, France. 3Department of Epidemiology and Biostatistics, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands. 4Department of Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan. 5Department of Gastroenterology and Hepatology, Osaka University Hospital, Osaka, Japan. This study was supported by an unrestricted grant from Minophagen Pharmaceutical Co Ltd., Japan.
Page 1:
Statistical Models of Treatment Eff
Page 4 and 5:
ISBN: 978-90-8559-069-9 © Bettina
Page 6 and 7:
PROMOTIECOMMISSIE Promotor: Prof.dr
Page 9 and 10:
CONTENTS Chapter 1. Introduction 11
Page 13:
Cha pter 1 Introduction
Page 16 and 17:
Chapter 1 14 Epidemiology Worldwide
Page 18 and 19:
Chapter 1 16 Prediction models with
Page 20 and 21:
Chapter 1 18 standard method fails
Page 22 and 23:
Chapter 1 20 The extended non-linea
Page 24 and 25:
Chapter 1 22 References 1. Blumberg
Page 27:
Cha pter 2 Prediction of response t
Page 30 and 31:
Chapter 2.1 28 ABSTRACT The aim of
Page 32 and 33:
Chapter 2.1 30 been hepatitis B sur
Page 34 and 35:
Chapter 2.1 32 HBV DNA decline The
Page 36 and 37:
Chapter 2.1 34 Figure 2 continued.
Page 38 and 39:
Chapter 2.1 36 Figure 4. Estimated
Page 40 and 41:
Chapter 2.1 38 DNA was observed in
Page 42:
Chapter 2.1 40 15. Kao JH. Role of
Page 46 and 47:
Chapter 2.2 44 ABSTRACT Background:
Page 48 and 49:
Chapter 2.2 46 low baseline HBV DNA
Page 50 and 51:
Chapter 2.2 48 patient subgroups wa
Page 52 and 53:
Chapter 2.2 50 p=0.002). Previous I
Page 54 and 55:
Chapter 2.2 52 Application of the m
Page 56 and 57:
Chapter 2.2 54 PEG-IFN, the proport
Page 58 and 59:
Chapter 2.2 56 References 1. Lavanc
Page 60 and 61:
Chapter 2.2 58 26. Bonino F, Lau GK
Page 63 and 64:
Chap ter 2.3 Prediction of the resp
Page 65 and 66:
INTRODUCTION Dynamic prediction of
Page 67 and 68:
Statistical analysis Dynamic predic
Page 69 and 70:
Dynamic prediction of response to P
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
References Dynamic prediction of re
Page 81 and 82:
Cha pter 2.4 Dynamic prediction of
Page 83 and 84:
INTRODUCTION Dynamic prediction of
Page 85 and 86:
For the indirect approach we rewrit
Page 87 and 88:
logit pi,j = logit Pr(Ri =1|visit =
Page 89 and 90: Dynamic prediction of response usin
Page 101 and 102: Table 1. Results of different stopp
Page 105: Dynamic prediction of response usin
Page 108 and 109: Chapter 2.5 106 ABSTRACT Peginterfe
Page 110 and 111: Chapter 2.5 108 and placebo daily.
Page 112 and 113: Chapter 2.5 110 for patients with a
Page 114 and 115: Chapter 2.5 112 Mean HBV DNA declin
Page 116 and 117: Chapter 2.5 114 peginterferon and n
Page 118 and 119: Chapter 2.5 116 hepatocellular carc
Page 120 and 121: Chapter 2.5 118 13. Werle-Lapostoll
Page 122: Chapter 2.5 120 Greece - G Germanid
Page 127 and 128: Chap ter 3.1 Long-term clinical out
Page 129 and 130: INTRODUCTION Glycyrrhizin for IFN-n
Page 131 and 132: Statistics Glycyrrhizin for IFN-non
Page 133 and 134: Glycyrrhizin for IFN-non responders
Page 135 and 136: Table 2. Time dependent Cox regress
Page 137 and 138: Glycyrrhizin for IFN-non responders
Page 139: Glycyrrhizin for IFN-non responders
Page 144 and 145: Chapter 3.2 142 Abstract We have de
Page 146 and 147: Chapter 3.2 144 multiple markers wa
Page 148 and 149: Chapter 3.2 146 The correlation bet
Page 150 and 151: Chapter 3.2 148 for our MLMM is fac
Page 152 and 153: Chapter 3.2 150 X and Z matrices fr
Page 154 and 155: Chapter 3.2 152 For each g =0,...,G
Page 156 and 157: Chapter 3.2 154 Focus of marginal,
Page 158 and 159: Chapter 3.2 156 Figure 1. Dutch PBC
Page 160 and 161: Chapter 3.2 158 Table 2. Dutch PBC
Page 166 and 167: Chapter 3.2 164 effects correct the
Page 168 and 169: Chapter 3.2 166 References 1. Kuipe
Page 170 and 171: Chapter 3.2 168 32. Tsiatis AA, Dav
Page 172: Chapter 3.2 170 Table 4. Structure
Page 177 and 178: Cha pter 4.1 Viral dynamics during
Page 179 and 180: INTRODUCTION Viral dynamics during
Page 181 and 182: V(t) = V 0 { A exp (-λ 1 t ) + (1-
Page 183 and 184: Table 2. Dynamic parameters during
Page 185 and 186: Figure 1. Viral dynamics during and
Page 187 and 188: Viral dynamics during and after ent
Page 189 and 190: References Viral dynamics during an
Page 191:
Viral dynamics during and after ent
Page 194 and 195:
Chapter 4.2 192 ABSTRACT Tenofovir,
Page 196 and 197:
Chapter 4.2 194 PATIENTS AND METHOD
Page 198 and 199:
Chapter 4.2 196 2 Slow: decline bet
Page 200 and 201:
Chapter 4.2 198 Table 2. Parameter
Page 202 and 203:
Chapter 4.2 200 9.0 8.0 7.0 6.0 5.0
Page 204 and 205:
Chapter 4.2 202 release. Although w
Page 206 and 207:
Chapter 4.2 204 References 1. Perri
Page 208:
Chapter 4.2 206 29. Lewin SR, Ribei
Page 212 and 213:
Chapter 4.3 210 ABSTRACT Treatment
Page 214 and 215:
Chapter 4.3 212 HBV DNA quantifi ca
Page 216 and 217:
Chapter 4.3 214 The resulting model
Page 218 and 219:
Chapter 4.3 216 Figure 1. Median HB
Page 220 and 221:
Chapter 4.3 218 Table 2: Pharmacoki
Page 222 and 223:
Chapter 4.3 220 Figure 3. effects r
Page 224 and 225:
Chapter 4.3 222 13-14 This model ta
Page 226 and 227:
Chapter 4.3 224 References 1. Kane
Page 228 and 229:
Chapter 4.3 226 25. Wolters LM, Han
Page 231:
Cha pter 5 Summary and conclusion
Page 234 and 235:
Summary and conclusion 232 Therapy
Page 236 and 237:
Summary and conclusion 234 who deve
Page 238 and 239:
Summary and conclusion 236 fi t mod
Page 241:
Cha pter 6 Samenvatting en conclusi
Page 244 and 245:
Samenvatting en conclusie 242 posit
Page 246 and 247:
Samenvatting en conclusie 244 De ve
Page 248 and 249:
Samenvatting en conclusie 246 en na
Page 250:
Samenvatting en conclusie 248 In ee
Page 255 and 256:
DANKWOORD Dankwoord 253 Met oplucht
Page 257:
CUR RICULUM VITAE Curriculum Vitae
Page 260 and 261:
Bibliography 258 Mechanical factors
Page 262 and 263:
Bibliography 260 35. Wolters LM, Ha
Page 264 and 265:
Bibliography 262 Volume Measurement
Page 266 and 267:
Bibliography 264 Quantitative HBV D
Page 268 and 269:
Bibliography 266 to Peginterferon-a
Page 272:
ISBN: 978-90-8559-069-9
show all

View PDF Version - RePub - Erasmus Universiteit Rotterdam

Create successful ePaper yourself

Delete template?

Save as template?